Survival Outcomes in EGFR‐Mutant Non‐Small Cell Lung Cancer With Brain Metastases: Kaplan–Meier and Cox Regression Analyses Across Treatment Stages
Third-generation EGFR-TKIs are effective first-line options for BMs but show limited efficacy against uncommon mutations. Post-resistance regimens integrating ICIs, antiangiogenics, and chemotherapy may improve survival. Reassessment of genetic and PD-L1 status is critical for guiding sequential therapy.
Authors
- Ligang Xing (ORCID: https://orcid.org/0000-0002-0528-9048)
- Qiang Qiao (ORCID: https://orcid.org/0009-0000-9810-2088)
- Haoran Qi
- Xiaorong Sun (ORCID: https://orcid.org/0000-0001-8520-9556)
Institutions
- Shandong Tumor Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- The Clinical Respiratory Journal
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1111/crj.70085
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Department of Science and Technology of Shandong Province
- National Natural Science Foundation of China